IMGN
Immunogen, Inc.
Halal Rating :
Last Price
$31.24
Last updated:
Market Cap
-
7D Change
0.0%
1 Year Change
0.0%
Company Overview
Industries
Exchange
Next Earnings Date
ImmunoGen, Inc. is a biotechnology company focused on developing antibody-drug conjugates (ADCs) for the treatment of cancer. The company's lead product is ELAHERE (mirvetuximab soravtansine-gynx), which received FDA approval in November 2022 for treating platinum-resistant ovarian cancer. ImmunoGen generates revenue primarily through product sales and collaboration agreements.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2023 | $113.42m | $91.06m | - | $3.59m | 0.00% | 3.95% |
| June 30, 2023 | $83.15m | $91.74m | - | $4.4m | 0.00% | 4.79% |
| March 31, 2023 | $49.87m | $93.11m | - | $853000.0 | 0.00% | 0.92% |
Company Impact
Help us evaluate Immunogen, Inc.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.